Colgate-Palmolive (CL) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Colgate-Palmolive reported revenue of $4.94 billion for Q4 2024, a slight year-over-year decline of 0.1%, with an EPS of $0.91 compared to $0.87 a year ago, indicating a positive EPS surprise of +2.25% against the consensus estimate [1][2] Revenue Performance - North America net sales for Oral, Personal and Home Care reached $1.04 billion, exceeding the average estimate of $1.01 billion, reflecting a year-over-year increase of +3.7% [4] - Latin America net sales for Oral, Personal and Home Care were $1.11 billion, matching the average estimate but showing a decline of -7.2% year-over-year [4] - Africa/Eurasia net sales for Oral, Personal and Home Care were $269 million, surpassing the average estimate of $261.71 million, with a year-over-year increase of +2.7% [4] - Europe net sales for Oral, Personal and Home Care totaled $668 million, below the average estimate of $687.89 million, representing a year-over-year decline of -2.5% [4] - Asia Pacific net sales for Oral, Personal and Home Care were $724 million, closely aligning with the average estimate, showing a year-over-year increase of +3.7% [4] - Pet Nutrition net sales amounted to $1.14 billion, slightly below the average estimate of $1.17 billion, with a year-over-year increase of +2.3% [4] - Total Oral, Personal and Home Care net sales were $3.80 billion, matching the average estimate but reflecting a year-over-year decline of -0.8% [4] Profitability Metrics - Total operating profit for Oral, Personal and Home Care was $969 million, below the average estimate of $1.03 billion [4] - Corporate operating profit was reported at -$179 million, slightly better than the average estimate of -$184.13 million [4] - Pet Nutrition operating profit reached $275 million, exceeding the average estimate of $256.82 million [4] Stock Performance - Colgate-Palmolive shares returned +0.4% over the past month, underperforming the Zacks S&P 500 composite's +2.9% change, with a current Zacks Rank of 3 (Hold) indicating potential performance in line with the broader market [3]